Sustainability

Piramal Pharma Highlights ESG Success in New Sustainability Report
Management & Regulatory Piramal Pharma Highlights ESG Success in New Sustainability Report

Piramal Pharma is currently evaluating 38% of its critical suppliers against strict environmental, social, and governance criteria to ensure sustainability throughout the entire value chain. This initiative represents a fundamental shift in how the pharmaceutical industry approaches procurement,

Can Gene Editing Eliminate PRRS in North American Pork?
Management & Regulatory Can Gene Editing Eliminate PRRS in North American Pork?

The high cost of managing PRRS outbreaks in Mexico has become a primary threat to the business survival of multi-generational family farming operations. Across the North American continent, the swine industry has reached a pivotal moment in its struggle against Porcine Reproductive and Respiratory

Can Feedback Loops Perfect Control in Synthetic Biology?
Biotech & Bioprocessing Can Feedback Loops Perfect Control in Synthetic Biology?

Industrial biomanufacturing efficiency is often compromised because the behavior of a cell population can change significantly from the early phase to high-density growth. This phenomenon creates a fundamental disconnect between the highly controlled blueprints of synthetic biology and the messy,

How Can MASIC Solve the Challenges of Large-Scale DNA Synthesis?
Biotech & Bioprocessing How Can MASIC Solve the Challenges of Large-Scale DNA Synthesis?

The precision of orthogonal overlap design ensures that minor errors in initial chemical synthesis do not multiply into larger misassembled products. As biotechnology continues to accelerate into the mid-2020s, the ability to architect complex metabolic pathways and entirely new genomes has moved

Can Biomanufacturing Solve the Global Cocoa Crisis?
Management & Regulatory Can Biomanufacturing Solve the Global Cocoa Crisis?

Utilizing brewery-style fermentation tanks to cultivate cocoa cells allows manufacturers to maintain 100 percent supply-chain stability regardless of unpredictable weather patterns. This innovative methodology, pioneered by Boston-based biotechnology leader GALY, arrives at a critical juncture for

How Can Mankind Pharma Balance ESG Growth and Global Scaling?
Management & Regulatory How Can Mankind Pharma Balance ESG Growth and Global Scaling?

The company reported a consolidated revenue of ₹4,031 crore for the first quarter of fiscal year 2027, reflecting a significant 12.89% annual growth. This financial achievement underscores the robust performance of its domestic portfolio, which continues to outpace the general Indian pharmaceutical

Loading

Subscribe to our weekly news digest.

Join now and become a part of our fast-growing community.

Invalid Email Address
Thanks for Subscribing!
We'll be sending you our best soon!
Something went wrong, please try again later